Selank has experimental findings and small human studies behind it, but the data examined do not justify self-medication for anxiety or insomnia. I identified no medicinal product authorisation in France in the registries consulted on 16 October 2026. A spray marketed as a “nootropic” does not, by itself, answer questions about identity, efficacy and safety.
The first trap sometimes appears before the promises: the name Selank does not guarantee that the product being sold matches the molecule studied. A scientific reference can be accurate while its application to the bottle is completely unjustified.
This guide is for information only. It provides no dose, administration method, combination or purchasing source. To distinguish the two peptides often lumped together in advertisements, the Semax and Selank comparison complements this Selank-focused analysis.
Selank, tuftsin and product identity
A heptapeptide, not an interchangeable name
Selank is a synthetic peptide made up of seven amino acids, hence the term heptapeptide. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated as TKPRPGP. The FDA GSRS substance registry identifies it by this sequence and distinguishes the substance from its diacetate form, among other things.
Its structure incorporates the four residues of tuftsin, Thr-Lys-Pro-Arg, with Pro-Gly-Pro added. This structural relationship explains its experimental interest. It does not establish that every product bearing this name reproduces the effects of tuftsin or of a medicine studied.
The terminology helps identify mix-ups:
| Term encountered | What it refers to | What it does not demonstrate |
|---|---|---|
| Selank, TKPRPGP | A sequence of seven residues | The actual composition of a bottle |
| Tuftsin | A four-residue peptide whose sequence forms the beginning of Selank | Complete pharmacological equivalence |
| Selank acetate or diacetate | A chemical form with a counterion | An additional amino acid in the chain |
| N-acetyl-Selank or amidated derivative | A chemical modification requiring its own characterisation | Automatic applicability of findings from the Selank studied |
| “Octapeptide Selank” | A designation incompatible with the standard seven-residue sequence | The exact identity of the product or the source of the error |
Adding a counterion does not turn a heptapeptide into an octapeptide. Conversely, modifying one end of the molecule can change its properties without changing the number of residues. Counting to seven is useful, but not enough to certify a product.
The molecule and the finished product are two different things
A publication concerns a characterised substance, a formulation, a population and specific conditions. A commercial product introduces further unknowns: the identity of its contents, the actual quantity, excipients, impurities, stability and microbiological quality.
A CAS number identifies a substance in a documentation system. It certifies neither the contents nor the authorisation of the batch being sold. Nor does the label “for research use only” turn a laboratory product into a treatment intended for humans.
So there is no need to reproduce a commercial listing to assess a claim: if the product’s identity has not been established, the link to the cited study is already broken.
Animal data and human trials: keep them separate
Proposed mechanisms, not an established clinical effect
A 2018 mechanistic study explores Selank’s interactions with GABA binding using brain membrane preparations. This type of work can support a hypothesis about neurotransmission. It does not demonstrate that an adult will sleep better or feel less anxious in everyday life.
The phrase “acts on GABA” is not enough to equate Selank with a benzodiazepine either. A proposed mechanism, clinical efficacy and an adverse-effect profile are three questions that require separate evidence.
What the main publications examined show
The following table is a selection of relevant studies, not an exhaustive inventory of the literature. The human publications are assessed here mainly on the basis of their indexed abstracts: their full texts have not undergone a comprehensive methodological audit.
| Publication | Population and comparison | Reported result | Limitation for your decision |
|---|---|---|---|
| Zozulia and colleagues, 2008 | 62 patients with generalised anxiety or neurasthenia, 30 receiving Selank and 32 receiving medazepam | Anxiolytic effects described as similar on clinical scales | Small comparison in patients, with no proof of statistical equivalence established by the abstract alone |
| Medvedev and colleagues, 2014 | 60 patients with anxiety, phobic or somatoform disorders, comparison with phenazepam | Anxiolytic improvement and effects on quality of life reported | Abstract provides little detail on methods and numerical effects |
| Medvedev and colleagues, 2015 | 70 patients, 30 receiving phenazepam alone and 40 receiving it in combination with Selank | Favourable effects on certain symptoms and tolerability reported | Study of a combination in a clinical population, not of Selank alone in healthy adults |
| Panikratova and colleagues, 2020 | 52 healthy participants in total, Selank, Semax or placebo groups | Differences in resting-state brain connectivity | Acute imaging finding, not evidence of a lasting everyday benefit |
| Kasian and colleagues, 2017 | 48 male rats, with or without experimental stress, subgroups of six | Effect of the Selank–diazepam combination on a behavioural test | Animal model, with no validation of a combination in humans |
The human sources are the publications from 2008, 2014, 2015 and 2020. The animal study from 2017 is available in full text.
These studies rule out saying “there are no human data.” They are not enough to claim firmly established efficacy either. The abstracts of the comparative studies do not allow full verification of blinding, randomization, withdrawals, prespecified outcomes or the size of differences between groups. I do not reconstruct these details from the authors’ conclusions.
Several publications share researchers and institutions. These connections do not make the results false, but they do call for independent replication and transparent methods. The language or country of publication is no substitute for that assessment.
Anxiety and sleep: what remains unproven
A study in healthy volunteers does exist
The 2020 connectivity study includes 52 participants split across several groups, not 52 people all exposed to Selank. Functional MRI measurements were taken before, then five and twenty minutes after experimental administration.
A difference in amygdala connectivity indicates a change in the signal being studied. It does not automatically tell us whether someone feels better, works better, sleeps better or experiences a lasting benefit. Those claims would require relevant clinical outcomes, an appropriate comparison and sufficient follow-up.
Saying the brain reacted is not enough to say it worked better.
Patients with anxiety do not represent all stressed adults
Participants in the 2008 and 2014 trials had clinical disorders. Their results cannot be applied without qualification to a healthy adult looking to improve concentration or cope better with a busy week.
Likewise, an improvement described as similar to that of an active comparator does not prove therapeutic equivalence. That conclusion requires a method designed to test it, a defined margin and sufficient statistical precision. The word “comparable” in an abstract does not do that work.
Sleep claims go beyond the results presented
The sources reviewed do not provide robust clinical evidence for treating insomnia with Selank alone. An overall anxiety score, an observation of sedation or a change on imaging is no substitute for sleep outcomes assessed in an appropriately designed trial.
The 2015 study notably reports changes in adverse effects during phenazepam treatment, including increased sleep duration. That does not mean Selank improves restorative sleep in a healthy adult. The study concerns a combination and effects related to the comparator treatment.
In particular, convincing answers are missing on lasting benefit, relapses, quality of life and long-term safety for the uses promoted online. Insufficient evidence does not establish absolute ineffectiveness. It does prevent presenting the promise as a given.
Interactions, contamination and unknown safety
Why the diazepam study does not offer a combination to copy
In the 2017 study, researchers observed rats subjected to a stress model, using a maze test. The result also depends on the experimental context: repeated handling and administration are themselves discussed as stress factors.
This setup measures neither a clinical reduction in anxiety in humans nor the safety of a combination. The small 2015 human comparative study, meanwhile, concerns phenazepam, another benzodiazepine. It does not validate adding Selank to diazepam, a sleeping pill or an antidepressant.
So I am not offering any list of supposedly “compatible” combinations. A lack of interaction studies is not evidence of no interactions. Do not replace or change a prescribed treatment based on these experiments.
Product risks go beyond the molecule itself
The FDA flags a potential risk with Selank acetate of immunogenicity for certain routes of administration, linked in particular to aggregation and peptide impurities. It states that it lacks important information about its safety in humans.
Immunogenicity means the ability to trigger an immune response. This US regulatory signal does not quantify how often an adverse effect occurs and is not a French regulatory decision. It does, however, contradict the idea that a short chain of amino acids must be harmless.
The DGCCRF highlights the risks of medicines sold outside authorized channels. For Selank, I have no investigation available that would allow an estimate of the proportion of contaminated or incorrectly dosed batches. So I do not turn this general risk into a specific contamination rate.
A chemical purity certificate alone does not answer every question about the finished product: identity, concentration, microbial contaminants, stability and whether it matches the batch used. A safety dossier is more than a percentage printed on a document.
What cannot be guaranteed
The data presented cannot guarantee the absence of dependence, cognitive problems or rare effects after prolonged use. Nor do they establish safety during pregnancy, breastfeeding or in minors.
If you have already been exposed and experience an unusual symptom, tell a doctor or pharmacist, naming the product and any other substances taken. Keep the packaging to help with identification. Difficulty breathing, facial swelling, severe confusion or feeling seriously unwell warrant urgent help, including calling 15 or 112 in France. These are general warning signs, not rates of effects attributed to Selank.
Status in France: registers checked at the time of writing
Check results as of October 16, 2026
I searched for Selank, Selanc and the variants tuftsin/tuftsine in the relevant downloadable files, then cross-checked against EMA medicines data. Here is the exact scope:
| Official source | Check performed | Result and scope |
|---|---|---|
| French public medicines database, medicinal products file | Product names, file dated September 29, 2026 | No matches found for the search terms |
| Same database, composition file | Declared substances, same file date | No matches found for the search terms |
| EMA, medicines table | Names, substances and other text fields, export from October 16, 2026 at 6 a.m. | No matches found within the scope of the EMA catalogue |
The French files are accessible through the BDPM. The EMA provides its medicines data table and notes that its catalogue does not cover all national authorisations.
I therefore identified no French or centralised European marketing authorisation corresponding to Selank in these sources. This check is not an exhaustive search of all exceptional access schemes, nor a legal analysis of possession or importation. Nor does it establish that a product is authorised as a food supplement.
A claim of registration abroad does not prove authorisation in France. I am not presenting any current Russian status here as verified: that would require a separate check of the exact product and the relevant register.
Being on sale is not a health authority endorsement
A spray listed on a marketplace, a product page in French or an offer of delivery does not demonstrate any authorisation. These are commercial elements.
The same reasoning applies to a substance identifier: being listed in GSRS does not mean being approved by the FDA. A chemical identity register and an authorisation register answer different questions.
If a page claims authorisation, the relevant evidence is a verifiable decision tied to the product, its authorisation holder and its indication. A catalogue screenshot or a link to an animal study is no substitute.
